


| ERLEADA® (apalutamide) Significantly Improved Overall Survival (OS) and Radiographic Progression-Free Survival (rPFS) in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) |
|
CHICAGO May 31, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today findings from the investigational Phase 3 TITAN study, which showed the addition of ERLEADA ® (apalutamide) to androgen deprivation therapy (ADT) compared with placebo plus ADT....
Posted: 2019-06-01 00:52:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.